Tevogen (TVGN) Preferred Stock Liabilities (2021 - 2023)
Tevogen Bio Holdings' (TVGN) quarterly Preferred Stock Liabilities came in at $16.7 million in Q4 2023, down 95.33% YoY from $356.9 million in Q4 2022, and down 35.87% on a QoQ basis from $26.0 million in Q3 2023.
Tevogen (TVGN) Preferred Stock Liabilities (2021 - 2023) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 3 years of Preferred Stock Liabilities data on file, last reported at $16.7 million in Q4 2023.
- Quarterly Preferred Stock Liabilities fell 95.33% year-over-year to $16.7 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $16.7 million (down 95.33% YoY) and the FY2023 annual result came in at $16.7 million, down 95.33% from the prior year.
- Preferred Stock Liabilities fell to $16.7 million in Q4 2023, from $26.0 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $356.9 million in Q4 2022 to a low of $16.7 million in Q4 2023.
- A 3-year average of $206.7 million and a median of $351.9 million in 2021 frame the typical range for Preferred Stock Liabilities.
- Annual changes were most pronounced in 2022 — Preferred Stock Liabilities increased 1.41% — and 2023, when it sank 95.33%.
- Tracing TVGN's Preferred Stock Liabilities over 3 years: stood at $351.9 million in 2021, then rose by 1.41% to $356.9 million in 2022, then slumped by 95.33% to $16.7 million in 2023.
- The last three Preferred Stock Liabilities figures came in at $16.7 million (Q4 2023), $26.0 million (Q3 2023), and $25.7 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 16.68 Mn |
| Sep 30, 2023 | 26.01 Mn |
| Jun 30, 2023 | 25.68 Mn |
| Mar 31, 2023 | 25.37 Mn |
| Dec 31, 2022 | 356.86 Mn |
| Sep 30, 2022 | 354.12 Mn |
| Jun 30, 2022 | 351.90 Mn |
| Mar 31, 2022 | 351.90 Mn |
| Dec 31, 2021 | 351.90 Mn |